Galmed Pharmaceuticals Ltd chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share N/A
Dividend & YieldN/A$ (N/A)
Beta 1.51
Market capitalization 7.51M
Operating cash flow -21.47M
ESG Scores unknown

Company description

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.

Sector: Healthcare - Industry: Biotechnology

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities -1M 4.18M 1.05M
Total Cashflows From Investing Activities -60.02M 6.68M 16.54M
Net Borrowings
Total Cash From Financing Activities 80.18M 143k 768k
Change To Operating Activities -142k -144k 8k
Issuance Of Stock 80.18M 143k 768k
Net Income -9.86M -20.46M -28.77M
Change In Cash 11.14M -8.12M -8.98M
Effect Of Exchange Rate
Total Cash From Operating Activities -9.02M -14.94M -26.29M
Depreciation 387k 35k 39k
Change To Account Receivables -63k -609k 15k
Other Cashflows From Financing Activities
Change To Netincome 1.65M 2.06M 1.38M
Capital Expenditures -90k -12k -44k

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 8.31M 18.18M 26.08M
Income Before Tax -9.78M -20.46M -28.77M
Net Income -9.86M -20.46M -28.77M
Selling General Administrative 4.44M 4.2M 4.13M
Gross Profit 2.04M
Ebit -10.71M -22.38M -30.21M
Operating Income -10.71M -22.38M -30.21M
Interest Expense
Income Tax Expense 75k
Total Revenue 2.04M
Cost Of Revenue
Total Other Income ExpenseNet 934k 1.92M 1.44M 414k
Net Income From Continuing Ops -9.86M -20.46M -28.77M
Net Income Applicable To Common Shares -9.86M -20.46M -28.77M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 2.71M 7.29M 8.23M
Total Stockholder Equity 87.89M 69.85M 44.15M
Other Current Liabilities 892k 935k 966k 818k
Total Assets 90.6M 77.14M 52.38M
Common Stock 58k 58k 58k
Other Current Assets 112k 113k
Retained Earnings -86.47M -106.94M -135.71M
Treasury Stock -11k 35k 272k
Cash 24.16M 15.93M 6.95M
Total Current Liabilities 2.71M 6.93M 8.01M
Other Stockholder Equity -11k 35k 272k
Property, Plant, and Equipment 194k 709k 570k
Total Current Assets 90.41M 76.43M 51.81M
Net Tangible Assets 87.89M 69.85M 44.15M
Net Receivables 51k 226k 66k 79k
Accounts Payable 1.81M 6M 7.05M


Insider Transactions

Here are the insider transactions of stock shares related to Galmed Pharmaceuticals Ltd:

Filer Name Transaction Text Ownership Date Filer Relation Shares
NO DATA

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Galmed Pharmaceuticals Ltd. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Galmed Pharmaceuticals Ltd

Here is the result of two systematic investment strategies applied to Galmed Pharmaceuticals Ltd. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Galmed Pharmaceuticals Ltd

The following chart shows the equity curve of the two systematic investment strategies applied to Galmed Pharmaceuticals Ltd:

Galmed Pharmaceuticals Ltd automated entries

The systematic investment strategy that buys the first day of the month would give a performance of -50.84% on the backtest period.

Performance at glance

Performance

-50.84 %

Latent gain

-891.91 $

Invested capital

1754.31 $

Annualized return

-12.4 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Galmed Pharmaceuticals Ltd

This is the result of two momentum investment strategies applied to Galmed Pharmaceuticals Ltd. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Galmed Pharmaceuticals Ltd

The following chart shows all the entries opened by the momentum investment system on Galmed Pharmaceuticals Ltd:

Galmed Pharmaceuticals Ltd momentum entries
  • The first momentum investment strategy would give -39.14% of return on Galmed Pharmaceuticals Ltd. That represents -2255.86$ of latent gain with 5764.26$ of employed capital.
  • The second momentum investment strategy would give -37.55% of return on Galmed Pharmaceuticals Ltd. That represents -1033.79$ of latent gain with 2752.99$ of employed capital.
Performance at glance (1Q Momentum)

Performance

-39.14 %

Latent gain

-2255.86 $

Invested capital

5764.26 $

Annualized return

0.0 %
Performance at glance (2Q Momentum)

Performance

-37.55 %

Latent gain

-1033.79 $

Invested capital

2752.99 $

Annualized return

-10.37 %

Momentum equity curve on Galmed Pharmaceuticals Ltd

The following chart shows the equity curve of the two momentum strategies applied to Galmed Pharmaceuticals Ltd:

Galmed Pharmaceuticals Ltd momentum equity

Note: the dividends potentially given by Galmed Pharmaceuticals Ltd are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Galmed Pharmaceuticals Ltd

The following chart shows the employed capital evolution of the two momentum strategies on Galmed Pharmaceuticals Ltd since the beginning:

Galmed Pharmaceuticals Ltd

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Galmed Pharmaceuticals Ltd

Buy the dip entry openings on Galmed Pharmaceuticals Ltd

Galmed Pharmaceuticals Ltd

The performance achieved by the robo-advisor on Galmed Pharmaceuticals Ltd is 0%. That represents 0.0$ of latent gain with 0.0$ of employed capital. The following chart shows Galmed Pharmaceuticals Ltd stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Galmed Pharmaceuticals Ltd, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

0 %

Latent gain

0.0 $

Invested capital

0.0 $

Annualized return

0.0 %

Equity curve of the strategy applied to Galmed Pharmaceuticals Ltd

The following chart shows the result of the investment strategy applied to Galmed Pharmaceuticals Ltd:

Galmed Pharmaceuticals Ltd

Note: the dividends potentially given by Galmed Pharmaceuticals Ltd are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Galmed Pharmaceuticals Ltd

The following chart shows the employed capital evolution since the beginning of the investment strategy on Galmed Pharmaceuticals Ltd:

Galmed Pharmaceuticals Ltd

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Galmed Pharmaceuticals Ltd

In this section, I will compare the three previous investment strategies applied to Galmed Pharmaceuticals Ltd.

Equity curve comparison on Galmed Pharmaceuticals Ltd

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Galmed Pharmaceuticals Ltd investment strategy comparison

Employed capital comparison on Galmed Pharmaceuticals Ltd

Galmed Pharmaceuticals Ltd investment comparison

Performance comparison on Galmed Pharmaceuticals Ltd

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment -50.84% -891.91$ 1754.31$ -12.4%
Momentum 1 quarter -39.14% -2255.86$ 5764.26$ -10.14%
Momentum 2 quarters -37.55% -1033.79$ 2752.99$ -10.37%
Non-directional 0% 0.0$ 0.0$ 0.0%
Annualized return comparison

Automatic investment

-12.4 %

Momentum 1Q

-10.37 %

Momentum 2Q

-10.37 %

Non-directional

0.0 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Galmed Pharmaceuticals Ltd:

Positive correlations

Most correlated stocks this year

  • Galmed Pharmaceuticals Ltd

  • Most correlated stocks last 3 months

  • Galmed Pharmaceuticals Ltd
  • ENERFLEX LTD
  • ProShares Ultra Yen 2x Shares

  • Negative correlation

    Most negatively correlated stocks this year


    Most negatively correlated stocks last 3 months

  • ProShares UltraShort Yen -2x Shares

  • Note: The algorithm computes the probability of correlation between Galmed Pharmaceuticals Ltd and the other stocks. There may be false positives or some missing correlated stocks. If the price of Galmed Pharmaceuticals Ltd does not vary for 36 weeks, the correlation calculation result will be wrong.


    Company information

    Company name Galmed Pharmaceuticals Ltd
    Country Israel
    City Tel Aviv
    Address 16 Tiomkin Street
    Phone 972 3 693 8448
    Website www.galmedpharma.com
    FullTime employees 19
    Industry Biotechnology
    Sector Healthcare
    Exchange XNAS
    Ticker GLMD
    Market www.nasdaq.com

    Galmed Pharmaceuticals Ltd ESG Scores

    Environment scores

    Environment ESG Factors Scores
    Environment Score 0
    Peer Environment Performance unknown
    Environment Percentile unknown
    Palm Oil unknown
    Nuclear unknown
    Fur Leather unknown
    GMO unknown
    Coal unknown
    Pesticides unknown
    Animal Testing unknown

    Social scores

    Social ESG Factors Scores
    Social Score 0
    Peer Social Performance unknown
    Social Percentile unknown
    Highest Controversy unknown
    Peer Highest Controversy Performance unknown
    Adult unknown
    Gambling unknown
    Alcoholic unknown
    Tobacco unknown
    Catholic unknown
    Controversial Weapons unknown
    Small Arms unknown
    Military Contract unknown
    Peer Count unknown

    Related Controversy:


    Governance scores

    Governance ESG Factors Scores
    Governance Score 0
    Peer Governance Performance unknown
    Governance Percentile unknown

    ESG at glance
    Total ESG Scores: unknown
    Environment Score: 0
    Social Score: 0
    Governance Score: 0

    ESG Performance: unknown

    Peer Group: unknown

    Peer Esg Score Performance: unknown

    Rating Year: unknown

    Rating Month: unknown

    Max Age: unknown

    Percentile: unknown